Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the AACR Annual Meeting 2026 on April 17, 2026, in San Diego.

Rhea-AI Summary

Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the AACR Annual Meeting 2026 on April 17, 2026, in San Diego. The educational session, “Engineered NK Cells: From Innate Immunity to Clinical Innovation,” will highlight advances in Senti’s logic-gated SENTI-202 cell therapy and recent clinical trial results in relapsed/refractory acute myeloid leukemia.

The presentation will run 3:00–4:30 PM PT and will discuss how Logic Gates aim to increase therapeutic windows and improve precision in oncology cell therapies.

Argus Apr 13 session

+3.26% close to close Open Argus

Details

News Market Reaction – SNTI

In the Apr 13 session, SNTI gained 3.26%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Senti’s participation in an AACR educational session on engineered NK c...

Analysis

This announcement highlights Senti’s participation in an AACR educational session on engineered NK cells and Logic-Gated SENTI-202, underscoring its focus on relapsed/refractory acute myeloid leukemia and broader oncology applications. Recent history shows mixed market responses to conferences and scientific updates, with moves ranging from -2.17% to +7.08%. Investors may watch how AACR discussions complement earlier SENTI-202 data, RMAT designation, and ongoing Gene Circuit platform progress.

Key Figures

Conference dates: April 17–22, 2026 Session date: April 17, 2026 Session time: 3:00–4:30 PM PT +5 more

Conference dates

April 17–22, 2026

AACR Annual Meeting 2026 in San Diego, CA

Session date

April 17, 2026

Educational session featuring Senti CEO at AACR

Session time

3:00–4:30 PM PT

AACR educational session on engineered NK cells

Indication

Relapsed/refractory acute myeloid leukemia

SENTI-202 clinical trial results highlighted

Current price

$0.8729

Price before AACR presentation news on Apr 13, 2026

52-week high

$5.10

Pre-news 52-week high level

52-week low

$0.7702

Pre-news 52-week low level

Market cap

$26,946,219

Pre-news market capitalization

Historical Context

5 past events · Latest: Apr 01

5 events

1. Apr 01

   Scientific publication

   24h Move

   +3.3%

   Cell Systems paper on NOT-gated CAR circuits showing selective tumor killing.

2. Mar 27

   Earnings and update

   24h Move

   -10.4%

   Full-year 2025 results with significant net loss alongside RMAT and pipeline updates.

3. Mar 23

   Conference presentation

   24h Move

   -2.2%

   Announcement of SENTI-202 data presentations at Innate Killer conference.

4. Mar 03

   Investor conference

   24h Move

   +2.1%

   CEO presentation at Leerink Partners healthcare conference with webcast access.

5. Feb 24

   Investor conference

   24h Move

   +7.1%

   TD Cowen conference talk on Gene Circuit platform, pipeline, and partnerships.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

engineered nk cells, logic-gated, cell therapy, t cell engagers, +2 more

6 terms

engineered nk cells medical

"Dr. Lu will participate in an educational session titled “Engineered NK Cells: From Innate"

Engineered NK cells are immune cells taken from donors or grown in the lab and modified to better recognize and kill cancer or infected cells, like upgrading a security guard with a new badge and key to find intruders faster. They matter to investors because they represent a potential high-value class of therapies with commercial upside, but bring development, manufacturing and regulatory risks that affect company valuations and timelines.

logic-gated medical

"development of Senti’s engineered Logic-Gated SENTI-202 cell therapy and the broader"

An engineering approach used mainly in therapies and diagnostics where the product only activates when specific biological conditions are met, using built‑in “if‑this‑and/then‑that” rules. It matters to investors because it can reduce side effects and failed trials by making treatments more precise, potentially smoothing regulatory review and improving commercial prospects — like a smart lock that opens only with the right combination, avoiding accidental triggers.

cell therapy medical

"development of Senti’s engineered Logic-Gated SENTI-202 cell therapy and the broader"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

t cell engagers medical

"biologics, such as T cell engagers and antibody-drug conjugates, and conventional"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

antibody-drug conjugates medical

"biologics, such as T cell engagers and antibody-drug conjugates, and conventional"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

acute myeloid leukemia medical

"SENTI-202 clinical trial results in relapsed/refractory acute myeloid leukemia and other"

A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.

Dr. Lu will participate in an educational session titled “Engineered NK Cells: From Innate Immunity to Clinical Innovation.” The session will highlight advances in the development of Senti’s engineered Logic-Gated SENTI-202 cell therapy and the broader potential for Logic Gates to address a wide range of unmet needs in oncology.

Presentation Details:

• Session Title: Engineered NK Cells: From Innate Immunity to Clinical Innovation
• Session Type: Educational Session
• Presenter: Timothy Lu, Co-Founder & CEO, Senti Biosciences
• Date: Friday, April 17, 2026
• Time: 3:00 – 4:30 PM PT
• Location: AACR Annual Meeting 2026, San Diego, CA

“We are honored to contribute to this important educational session at AACR,” said Dr. Lu. “Our Logic-Gated cell therapies selectively kill cancer cells while protecting healthy cells. Enhanced therapeutic windows from Logic Gates enable the treatment of cancers for which conventional single-target biologics, such as T cell engagers and antibody-drug conjugates, and conventional single-target cell therapies are unable to perform. We look forward to sharing insights from our recent SENTI-202 clinical trial results in relapsed/refractory acute myeloid leukemia and other applications of our Logic Gates to improve precision and efficacy for cancer therapies.”

The AACR Annual Meeting is one of the leading global conferences for cancer research, bringing together scientists, clinicians, and industry leaders to discuss the latest advances in cancer science and medicine. For more information, please visit the conference website here.

About Senti Bio

Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

Availability of Other Information About Senti Biosciences, Inc.

For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Senti Biosciences (SNTI) present at AACR 2026?

Senti Biosciences will present on April 17, 2026, 3:00–4:30 PM PT in San Diego. According to the company, CEO Timothy Lu will speak in an educational session on engineered NK cells and logic-gated cell therapies at the AACR Annual Meeting.

What will Senti discuss about SENTI-202 at the AACR session on April 17, 2026?

Senti will discuss advances and recent clinical trial results for SENTI-202 in relapsed/refractory AML. According to the company, the talk will focus on SENTI-202 data and how logic gates may improve selectivity and therapeutic windows in oncology.

How do Senti’s Logic Gates aim to impact cancer cell therapy work discussed at AACR 2026?

Logic Gates are designed to increase tumor selectivity while sparing healthy cells, improving therapeutic windows. According to the company, the session will explain how these circuits enable treatments where single-target biologics and cell therapies may fall short.

Who is presenting for Senti Biosciences (SNTI) at the AACR 2026 educational session?

Timothy Lu, Co-Founder and CEO of Senti Biosciences, will present the session on April 17, 2026. According to the company, Dr. Lu will cover engineered NK cells and Senti’s logic-gated approach, including SENTI-202 clinical observations.

Will the AACR 2026 presentation include clinical trial results for Senti’s programs?

Yes, the presentation will include recent clinical trial results for SENTI-202 in relapsed/refractory AML. According to the company, Dr. Lu will share insights from those SENTI-202 clinical observations and discuss broader applications of Logic Gates.

How can investors use Senti’s AACR presentation on April 17, 2026 to assess SNTI progress?

Investors can view the presentation for technical and clinical context on SENTI-202 and logic-gated platforms. According to the company, the session will provide updates on clinical data and platform advances relevant to Senti’s oncology strategy.